Discovery of New Phenyltetrazolium Derivatives as Ferroptosis Inhibitors for Treating Ischemic Stroke: An Example Development from Free Radical Scavengers-Reference-Cited by-同舟云学术

Discovery of New Phenyltetrazolium Derivatives as Ferroptosis Inhibitors for Treating Ischemic Stroke: An Example Development from Free Radical Scavengers

Published:2024-07-12 Issue:14 Volume:67 Page:11712-11731
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Lu Yang¹²,Shen Zexu¹,Xu Yaping²,Lin Haoran¹,Shen Liteng²,Jin Yizhen²,Guo Yu²^ORCID,Lu Jialiang²,Li Linjie²,Zhuang Yuxin²,Jin Yuheng²,Zhuang Weihao²,Huang Wenhai³⁴,Dong Xiaowu¹²⁵⁶^ORCID,Dai Haibin¹,Che Jinxin²⁵⁶^ORCID

Affiliation:

1. Department of Pharmacy, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China

2. Hangzhou Institute of Innovative Medicine, Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China

3. Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, Institute of Materia Medica, Hangzhou Medical College, Hangzhou 310013, PR China

4. School of Pharmacy, Hangzhou Medical College, Hangzhou 310013, China

5. Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Hangzhou 310018, China

6. National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou 310058, China

Funder

Science Fund for Distinguished Young Scholars of Zhejiang Province

Key Research and Development Program of Zhejiang Province

National Natural Science Foundation of China

Natural Science Foundation of Zhejiang Province

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00211

Reference45 articles.

1. Ischaemic stroke

2. Global Epidemiology of Stroke and Access to Acute Ischemic Stroke Interventions

3. Performance of the ACC/AHA Pooled Cohort Cardiovascular Risk Equations in Clinical Practice

4. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source

5. Aspirin and Antiplatelet Agent Resistance